Prevymis

Active Ingredient(s): Letermovir
FDA Approved: * November 8, 2017
Pharm Company: * MERCK SHARP DOHME
Category: Antiviral

Letermovir (INN; trade name Prevymis) is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.[1] The drug was developed by Merck & Co.[2] The drug was granted fast track status by the US Food and Drug Administration (FDA) and o... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Prevymis 240 mg Oral Tablet, Film Coated
NDC: 0006-3075
Labeler:
Merck Sharp & Dohme Corp.
Prevymis 480 mg Oral Tablet, Film Coated
NDC: 0006-3076
Labeler:
Merck Sharp & Dohme Corp.
Prevymis 20 mg/ml Intravenous Injection, Solution
NDC: 0006-5003
Labeler:
Merck Sharp & Dohme Corp.
Prevymis 20 mg/ml Intravenous Injection, Solution
NDC: 0006-5004
Labeler:
Merck Sharp & Dohme Corp.